| |
 |
|
Class Information
Number: 514/1
Name: Drug, bio-affecting and body treating compositions > Designated organic active ingredient containing (doai)
Description: Subject matter under Class 424 definition which contains a designated organic active ingredient, e.g., coal tar, coal tar oil, etc.
Sub-classes under this class:
| Class Number |
Class Name |
Patents |
| 514/ |
Heterocyclic carbon cpmpounds containing a hetero ring having chalcogen (i.e., o,s,se or te) or nitrogen as the only ring hetero atoms doai |
0 |
| 514/149 |
Azoxy doai |
45 |
| 514/150 |
Acyclic nitrogen double bonded to acyclic nitrogen, acyclic nitrogen triple bonded to acyclic nitrogen or azide doai |
249 |
| 514/152 |
3,10-dihydroxy-2-naphthacene carboxamide or derivative (e.g., tetracycline, etc.) doai |
262 |
| 514/155 |
Para-n-benzene - sulfoxy-n containing doai, and said benzene ring is not part of a polycyclo ring system |
70 |
| 514/159 |
Ortho-hydroxybenzoic acid (i.e., salicyclic acid) or derivative doai |
316 |
| 514/167 |
9,10-seco- cyclopentanohydrophenanthrene ring system (e.g., vitamin d, etc.) doai |
570 |
| 514/169 |
Cyclopentanohydrophenanthrene ring system doai |
482 |
| 514/183 |
Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., o,s,se or te) or nitrogen as the only ring hetero atoms doai |
1,536 |
| 514/2 |
Peptide containing (e.g., protein, peptones, fibrinogen, etc.) doai |
7,165 |
| 514/22 |
Lignin or derivative doai |
44 |
| 514/23 |
Carbohydrate (i.e., saccharide radical containing) doai |
1,428 |
| 514/476 |
N-c(=x)x containing (x is chalcogen) doai |
158 |
| 514/492 |
Heavy metal containing doai |
578 |
| 514/506 |
Ester doai |
240 |
| 514/553 |
Radical -xh acid, or anhydride, acid halide or salt thereof (x is chalcogen) doai |
249 |
| 514/579 |
Nitrogen containing other than solely as a nitrogen in an inorganic ion of an addition salt, a nitro or a nitroso doai |
210 |
| 514/63 |
Silicon containing doai |
927 |
| 514/64 |
Boron containing doai |
192 |
| 514/65 |
Pyrethrum plant derived material or plant derived rotenone compound containing doai |
79 |
| 514/675 |
Ketone doai |
175 |
| 514/693 |
Aldehyde doai |
155 |
| 514/706 |
Sulfur, selenium or tellurium compound (e.g., thioalcohols, mercaptans, etc.) |
198 |
| 514/714 |
Peroxide doai |
121 |
| 514/715 |
Ether doai |
114 |
| 514/724 |
C-o-group (e.g., alcohol, alcoholate, etc.) doai |
479 |
| 514/740 |
Nitrogen containing compound doai |
95 |
| 514/743 |
Halogenated hydrocarbon doai |
68 |
| 514/75 |
Phosphorus containing other than solely as part of an inorganic ion in an addition salt doai |
256 |
| 514/762 |
Hydrocarbon doai |
163 |
Patents under this class:
| Patent Number |
Title Of Patent |
Date Issued |
| 7618615 |
Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia |
Nov. 17, 2009 |
| 7611729 |
Dosage forms having prolonged active ingredient release |
Nov. 3, 2009 |
| 7611833 |
Yeast genes that affect viral replication |
Nov. 3, 2009 |
| 7601368 |
Purified Arabinogalactan-Protein (AGP) composition useful in the treatment psoriasis and other disorders |
Oct. 13, 2009 |
| 7592319 |
Uses of DNA-PK |
Sep. 22, 2009 |
| 7592307 |
Releasable linkage and compositions containing same |
Sep. 22, 2009 |
| 7588901 |
Modulation of angiogenesis through targeting of arginyl transferase (ATE1) |
Sep. 15, 2009 |
| 7589056 |
Agent for the prevention and treatment of sexually transmitted diseases-I |
Sep. 15, 2009 |
| 7589057 |
Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
Sep. 15, 2009 |
| 7582317 |
Food supplements comprising, as a health component, sargahydroquinoic acid or derivative thereof |
Sep. 1, 2009 |
| 7582300 |
Modulation of gamma delta T cells to regulate airway hyperresponsiveness |
Sep. 1, 2009 |
| 7575767 |
Extraction of palm vitamin E, phytosterols and squalene from palm oil |
Aug. 18, 2009 |
| 7569536 |
Method for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity |
Aug. 4, 2009 |
| 7569551 |
Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
Aug. 4, 2009 |
| 7566454 |
Influenza nucleic acids, polypeptides, and uses thereof |
Jul. 28, 2009 |
| 7563618 |
Oligonucleotide conjugates |
Jul. 21, 2009 |
| 7560229 |
Methods of use of the enzymes of mycothiol synthesis |
Jul. 14, 2009 |
| 7547673 |
Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production |
Jun. 16, 2009 |
| 7547441 |
PAI-2 conjugates for the treatment and imaging of cancer |
Jun. 16, 2009 |
| 7534435 |
Glycosylated specificity exchangers |
May. 19, 2009 |
| 7534769 |
Compositions and methods for enhancing delivery of therapeutic agents to cells |
May. 19, 2009 |
| 7531499 |
Medicinal composition |
May. 12, 2009 |
| 7531500 |
Preventing airway mucus production by administration of EGF-R antagonists |
May. 12, 2009 |
| 7521414 |
Polyol macrolide antitumor-antibiotics from the marine actinomycete strain CNQ140 |
Apr. 21, 2009 |
| 7514397 |
Methods for inhibition of membrane-fusion-associated events, including Hepatitis B virus transmission |
Apr. 7, 2009 |
| 7507704 |
Receptor modulated cancer protocols |
Mar. 24, 2009 |
| 7507703 |
Method of cancer screening; method of cancer treatment; and method of diabetes treatment |
Mar. 24, 2009 |
| 7504208 |
Solid-phase fluorination of uracil and cytosine |
Mar. 17, 2009 |
| 7504477 |
Polyalkylene glycol acid additives |
Mar. 17, 2009 |
| 7494669 |
Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
Feb. 24, 2009 |
| 7465717 |
Process for releasing and extracting phosphatides from a phosphatide-containing matrix |
Dec. 16, 2008 |
| 7459443 |
Synthesis of biologically active compounds in cells |
Dec. 2, 2008 |
| 7449442 |
EGFR inhibitors promote axon regeneration |
Nov. 11, 2008 |
| 7423008 |
Derivatives of mithramycin and methods of making and uses thereof |
Sep. 9, 2008 |
| 7419683 |
Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules |
Sep. 2, 2008 |
| 7419964 |
Treatment of HSV-related pathologies using ssDNA |
Sep. 2, 2008 |
| 7405205 |
Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase |
Jul. 29, 2008 |
| 7402725 |
WIP, a WASP-associated protein |
Jul. 22, 2008 |
| 7390780 |
Gene delivery mediated by liposome-DNA complex with cleavable peg surface modification |
Jun. 24, 2008 |
| 7390497 |
Poly(ester amide) filler blends for modulation of coating properties |
Jun. 24, 2008 |
| 7384558 |
Compositions capable of inhibiting reactive oxygen and carbonyl species |
Jun. 10, 2008 |
| 7384907 |
Method of treating infection with ABl tyrosine kinase inhibitors |
Jun. 10, 2008 |
| 7375073 |
Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth |
May. 20, 2008 |
| 7371524 |
Substituted azaporphyrins as fluorescence labels |
May. 13, 2008 |
| 7365049 |
Afamin-containing compositions and methods of use |
Apr. 29, 2008 |
| 7358223 |
Biodegradable cationic polymers |
Apr. 15, 2008 |
| 7357928 |
Method for the diagnosis and prognosis of malignant diseases |
Apr. 15, 2008 |
| 7358222 |
Preventing airway mucus production by administration of EGF-R antagonists |
Apr. 15, 2008 |
| 7354894 |
Preventing airway mucus production by administration of EGF-R antagonists |
Apr. 8, 2008 |
| 7345018 |
Method of treating side effects induced by therapeutic agents |
Mar. 18, 2008 |
|
|
|
